c-Jun/AP-1 pathway-mediated cyclin D1 expression participates in low dose arsenite-induced transformation in mouse

Dongyun Zhang1, Jingxia Li, Jimin Gao

  • 1Nelson Institute of Environmental Medicine, New York University School of Medicine, 57 Old Forge Road, Tuxedo, NY 10987, USA.

Insights

Low dose arsenite exposure triggers skin cell transformation by activating the c-Jun/AP-1 pathway. This process involves cyclin D1, a key molecule in arsenite-induced carcinogenesis.

Area of Science:

  • Environmental Toxicology
  • Molecular Carcinogenesis
  • Dermatology

Background:

  • Arsenic is a known human carcinogen linked to skin cancer.
  • Previous research indicated arsenite induces cell transformation via ERK, not JNK pathways.

Purpose of the Study:

  • To investigate downstream pathways in low-dose arsenite-induced cell transformation.
  • To identify key molecular events in arsenite-mediated skin carcinogenesis.

Main Methods:

  • Utilized mouse epidermal JB6 Cl41 cells.
  • Assessed activation of c-Jun/AP-1 pathway.
  • Employed dominant-negative c-Jun (TAM67) and cyclin D1 siRNA.

Main Results:

  • Low-dose arsenite activated the c-Jun/AP-1 pathway.
  • TAM67 expression blocked arsenite-induced transformation.
  • Cyclin D1 inhibition impaired arsenite-induced anchorage-independent growth.

Conclusions:

  • c-Jun/AP-1 pathway activation is crucial for arsenite-induced cell transformation.
  • Cyclin D1 is a key downstream mediator in this process.
  • These findings elucidate mechanisms of skin carcinogenesis by low-dose arsenic.

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...